Tian Jun-Ping, Wang Tao, Wang Hong, Cheng Li-Tao, Tian Xin-Kui, Lindholm Bengt, Axelsson Jonas, Du Feng-He
Division of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Ren Fail. 2008;30(4):391-400. doi: 10.1080/08860220801964178.
Left ventricular hypertrophy (LVH) is common in dialysis patients, and an independent predictor of mortality. While recent studies have shown no differences in mortality between the two most common dialysis modalities, hemodialysis (HD) and peritoneal dialysis (PD), their impact on LVH is controversial. We thus performed cardiac ultrasound studies in prevalent dialysis patients receiving either HD or PD and compared LVH.
We included 48 HD and 62 PD patients receiving treatment for at least three months in our dialysis center. All patients underwent echocardiographic examination and blood pressure measurements immediately following therapy. Volume status was assessed by bioelectrical impedance analysis.
There was no baseline difference in demographics or comorbidities between HD and PD patients. As expected, extracellular water (ECW) in post-HD patients was significantly lower than that in pre-HD and PD patients, while cardiac output (CO) and systolic blood pressure (SBP) were higher in pre-HD than that in post-HD or PD patients. There was no significant difference in CO or SBP between post-HD and PD patients. Left ventricular mass index (LVMI) was markedly higher in HD patients as compared to PD patients. Thus, the prevalence of LVH according to the Framingham criteria was 68.8% in HD patients and 45.2% in PD patients. Subgroup analysis showed similar results in the patients who had been on single-modality dialysis for at least two years and in the anuric patients. Finally, in a linear regression model (r(2) = 0.364, p < 0.001), SBP, treatment modality (to be in HD), and ECW were all independent predictors of LVMI.
In a cross-sectional analysis of prevalent Chinese patients, we found a higher LVMI and a higher prevalence of LVH in HD than in PD patients. As LVMI was associated with high blood pressure and volume overload, we suggest that in these patients, PD may preserve more physiological hemodynamics even during long-term therapy.
左心室肥厚(LVH)在透析患者中很常见,并且是死亡率的独立预测因素。虽然最近的研究表明,两种最常见的透析方式,即血液透析(HD)和腹膜透析(PD),在死亡率方面没有差异,但它们对LVH的影响仍存在争议。因此,我们对接受HD或PD治疗的透析患者进行了心脏超声研究,并比较了LVH情况。
我们纳入了在我们透析中心接受治疗至少三个月的48例HD患者和62例PD患者。所有患者在治疗后立即接受超声心动图检查和血压测量。通过生物电阻抗分析评估容量状态。
HD患者和PD患者在人口统计学或合并症方面没有基线差异。正如预期的那样,HD治疗后的细胞外液(ECW)显著低于HD治疗前和PD患者,而HD治疗前的心输出量(CO)和收缩压(SBP)高于HD治疗后或PD患者。HD治疗后患者与PD患者之间的CO或SBP没有显著差异。与PD患者相比,HD患者的左心室质量指数(LVMI)明显更高。因此,根据弗雷明汉标准,HD患者的LVH患病率为68.8%,PD患者为45.2%。亚组分析显示,在接受单模式透析至少两年的患者和无尿患者中结果相似。最后,在一个线性回归模型(r² = 0.364,p < 0.001)中,SBP、治疗方式(HD)和ECW都是LVMI的独立预测因素。
在对中国现患患者的横断面分析中,我们发现HD患者的LVMI和LVH患病率高于PD患者。由于LVMI与高血压和容量超负荷相关,我们建议在这些患者中,即使在长期治疗期间,PD可能也能保持更生理的血流动力学状态。